HC Wainwright & Co. Maintains Buy on Immunogen, Raises Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a Buy rating on Immunogen (NASDAQ:IMGN) and raises the price target from $27 to $28.
November 03, 2023 | 11:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Immunogen and raises the price target from $27 to $28.
The maintained Buy rating and increased price target by HC Wainwright & Co. indicates a positive outlook for Immunogen. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100